| SYSTEMATIC REVIEW |
|
| Year : 2022 | Volume
: 8
| Issue : 3 | Page : 144-151 |
|
|
Effect of labetalol for treating patients with pregnancy-induced hypertension: A systematic review
Punyatoya Bej1, Sambhunath Das2
1 Associate Professor, Department of Community Medicine, Rama Medical College and Research Centre, Hapur, Uttar Pradesh, India
2 Professor, Department of Cardiac Anaesthesia, All India Institute of Medical Sciences, New Delhi, India
Correspondence Address:
Punyatoya Bej
Associate Professor, Department of Community Medicine, Rama Medical College and Research Centre, Hapur, Uttar Pradesh
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jpcs.jpcs_69_22
|
|
|
Pregnancy-induced hypertension (PIH) is one of the main causes of maternal mortality. Many first- and second-line drugs are available to treat the condition. Labetalol lowers blood pressure by blocking both α and β adrenergic receptors. It preserves uteroplacental blood flow efficiently. A systemic review was carried out to find the efficacy and safety of labetalol in the treatment of PIH. Three thousand twenty-six studies were retrieved in 20 years. Finally, 28 studies were selected after applying the review criteria. Twenty-three studies detected that labetalol had superior or similar action compared to other drugs in controlling hypertension in patients with preeclampsia and eclampsia. The systematic review concluded that labetalol is a safe, effective, first-choice of drug with few side effects in treating PIH.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
